 | • レポートコード：20QY06-05241 • 出版社/出版日：QYResearch / 2020年6月1日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、133ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、経口血糖降下薬及びインスリン類似体のグローバル市場について種類別（インスリン分泌促進薬、アルファグルコシダーゼ阻害剤、インスリン抵抗性改善薬）、用途別（病院、ドラッグストア、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・経口血糖降下薬及びインスリン類似体市場の概要 ・世界の主要地域別経口血糖降下薬及びインスリン類似体市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の経口血糖降下薬及びインスリン類似体市場規模2015-2026：種類別（インスリン分泌促進薬、アルファグルコシダーゼ阻害剤、インスリン抵抗性改善薬） ・世界の経口血糖降下薬及びインスリン類似体市場規模2015-2026：用途別（病院、ドラッグストア、その他） ・経口血糖降下薬及びインスリン類似体の北米市場規模2015-2020 ・経口血糖降下薬及びインスリン類似体のヨーロッパ市場規模2015-2020 ・経口血糖降下薬及びインスリン類似体の中国市場規模2015-2020 ・経口血糖降下薬及びインスリン類似体の日本市場規模2015-2020 ・経口血糖降下薬及びインスリン類似体の東南アジア市場規模2015-2020 ・経口血糖降下薬及びインスリン類似体のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Sanofi-Aventis、Ganlee、Biocon、Novo Nordisk、Eli Lilly、Tonghua Dongbao、United Laboratory、Jiangsu Wanbang） ・経口血糖降下薬及びインスリン類似体の製造コスト分析 ・販売チャネル、流通業者、顧客 ・経口血糖降下薬及びインスリン類似体の市場動向・機会・課題 ・調査の結論 |
QY Research aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview:
The global Oral Hypoglycemic Agents and Insulin Analogues market was valued at xx million US$ in 2019 and will reach xx million US$ by the end of 2026, growing at a CAGR of xx% during 2021-2026.
QY Research report provides an overview and scope of the global Oral Hypoglycemic Agents and Insulin Analogues market, stating its drivers, trends, opportunities, and restraints. The report also comprises all key details of the global Oral Hypoglycemic Agents and Insulin Analogues market such as market strategies, sales volumes, and consumption. The report also covers the names of all distribution channels such as manufacturers, suppliers, wholesalers, distributors, consumers, and dealers.
QY Research also presents the statistical data in the form of infographics, tables, and charts to predict the trends and developments of the global Oral Hypoglycemic Agents and Insulin Analogues market over the forecast period. The research analysts have also used a framework such as key industry experts interview, research papers, refer journals, survey reports, and face-to-face interviews with expert professionals to know the detailed outlook of the global Oral Hypoglycemic Agents and Insulin Analogues market. The report also includes nautical information, where it shows Oral Hypoglycemic Agents and Insulin Analogues market product volume, utilization value, and production processes.
The research report also consists of a competitive landscape that describes the top players that are functioning in the global Oral Hypoglycemic Agents and Insulin Analogues market. This report also describes the key developments and trends, mergers and acquisitions strategies, and new product innovation that will show an enormous benefit to the companies that are competing in the global Oral Hypoglycemic Agents and Insulin Analogues market.
Geographical Analysis:
Based on region, the global Oral Hypoglycemic Agents and Insulin Analogues market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Oral Hypoglycemic Agents and Insulin Analogues market are
Sanofi-Aventis
Ganlee
Biocon
Novo Nordisk
Eli Lilly
Tonghua Dongbao
United Laboratory
Jiangsu Wanbang
Segment by Type
Insulin Secretagogues
Alpha-glucosidase Inhibitors
Insulin Sensitizers
Segment by Application
Hospitals
Drug Store
Others
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Oral Hypoglycemic Agents and Insulin Analogues market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Oral Hypoglycemic Agents and Insulin Analogues market.
• The market share of the global Oral Hypoglycemic Agents and Insulin Analogues market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Oral Hypoglycemic Agents and Insulin Analogues market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Oral Hypoglycemic Agents and Insulin Analogues market.
Table of Contents
Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Report 2020
1 Oral Hypoglycemic Agents and Insulin Analogues Market Overview
1.1 Oral Hypoglycemic Agents and Insulin AnaloguesProduct Overview
1.2 Oral Hypoglycemic Agents and Insulin Analogues Segment by Type
1.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Comparison by Type (2015-2026)
1.2.2 Insulin Secretagogues
1.2.3 Alpha-glucosidase Inhibitors
1.2.4 Insulin Sensitizers
1.3 Oral Hypoglycemic Agents and Insulin Analogues Segment by Application
1.3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Comparison by Application (2015-2026)
1.3.2 Hospitals
1.3.3 Drug Store
1.3.4 Others
1.4 Oral Hypoglycemic Agents and Insulin Analogues Market by Region
1.4.1 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Comparison by Region (2015-2026)
1.4.2 North America Oral Hypoglycemic Agents and Insulin Analogues Status and Prospect (2015-2026)
1.4.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Status and Prospect (2015-2026)
1.4.4 China Oral Hypoglycemic Agents and Insulin Analogues Status and Prospect (2015-2026)
1.4.5 Japan Oral Hypoglycemic Agents and Insulin Analogues Status and Prospect (2015-2026)
1.4.6 Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Status and Prospect (2015-2026)
1.4.7 India Oral Hypoglycemic Agents and Insulin Analogues Status and Prospect (2015-2026)
1.5 Global Oral Hypoglycemic Agents and Insulin Analogues Sales and Revenue (2015-2026)
1.5.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2015-2026)
1.5.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate (2015-2026)
2 Oral Hypoglycemic Agents and Insulin Analogues by Company, Region, Type and Application
2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Competition by Companies
2.1.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share of Key Companies (2015-2020)
2.1.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Company (2015-2020)
2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales and Revenue by Region
2.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Region (2015-2020)
2.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region (2015-2020)
2.3 Global Oral Hypoglycemic Agents and Insulin Analogues Sales and Revenue by Type
2.3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2015-2020)
2.3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2015-2020)
2.4 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application
3 North America Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Price
3.1 North America Oral Hypoglycemic Agents and Insulin Analogues Sales and Revenue (2015-2020)
3.1.1 North America Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
3.1.2 North America Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2015-2020)
3.1.3 North America Oral Hypoglycemic Agents and Insulin Analogues Price Trend (2015-2020)
3.2 North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company
3.3 North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type
3.4 North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application
4 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Price
4.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales and Value (2015-2020)
4.1.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
4.1.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2015-2020)
4.1.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Price Trend (2015-2020)
4.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company
4.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type
4.4 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application
5 China Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Price
5.1 China Oral Hypoglycemic Agents and Insulin Analogues Sales and Revenue (2015-2020)
5.1.1 China Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
5.1.2 China Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2015-2020)
5.1.3 China Oral Hypoglycemic Agents and Insulin Analogues Price Trend (2015-2020)
5.2 China Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company
5.3 China Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type
5.4 China Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application
6 Japan Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Price
6.1 Japan Oral Hypoglycemic Agents and Insulin Analogues Sales and Value (2015-2020)
6.1.1 Japan Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
6.1.2 Japan Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2015-2020)
6.1.3 Japan Oral Hypoglycemic Agents and Insulin Analogues Price Trend (2015-2020)
6.2 Japan Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company
6.3 Japan Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type
6.4 Japan Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application
7 Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Price
7.1 Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales and Value (2015-2020)
7.1.1 Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
7.1.2 Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2015-2020)
7.1.3 Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Price Trend (2015-2020)
7.2 Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company
7.3 Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type
7.4 Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application
8 India Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Price
8.1 India Oral Hypoglycemic Agents and Insulin Analogues Sales and Value (2015-2020)
8.1.1 India Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
8.1.2 India Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2015-2020)
8.1.3 India Oral Hypoglycemic Agents and Insulin Analogues Price Trend (2015-2020)
8.2 India Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company
8.3 India Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type
8.4 India Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application
9 Company Profiles and Key Figures in Oral Hypoglycemic Agents and Insulin Analogues Business
9.1 Sanofi-Aventis
9.1.1 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
9.1.2 Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
9.1.3 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue, Price and Gross Margin (2015-2020)
9.1.4 Main Business and Markets Served
9.2 Ganlee
9.2.1 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
9.2.2 Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
9.2.3 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue, Price and Gross Margin (2015-2020)
9.2.4 Main Business and Markets Served
9.3 Biocon
9.3.1 Biocon Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
9.3.2 Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
9.3.3 Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue, Price and Gross Margin (2015-2020)
9.3.4 Main Business and Markets Served
9.4 Novo Nordisk
9.4.1 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
9.4.2 Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
9.4.3 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue, Price and Gross Margin (2015-2020)
9.4.4 Main Business and Markets Served
9.5 Eli Lilly
9.5.1 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
9.5.2 Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
9.5.3 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue, Price and Gross Margin (2015-2020)
9.5.4 Main Business and Markets Served
9.6 Tonghua Dongbao
9.6.1 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
9.6.2 Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
9.6.3 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue, Price and Gross Margin (2015-2020)
9.6.4 Main Business and Markets Served
9.7 United Laboratory
9.7.1 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
9.7.2 Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
9.7.3 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue, Price and Gross Margin (2015-2020)
9.7.4 Main Business and Markets Served
9.8 Jiangsu Wanbang
9.8.1 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
9.8.2 Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
9.8.3 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue, Price and Gross Margin (2015-2020)
9.8.4 Main Business and Markets Served
10 Oral Hypoglycemic Agents and Insulin Analogues Maufacturing Cost Analysis
10.1 Oral Hypoglycemic Agents and Insulin Analogues Key Raw Materials Analysis
10.1.1 Key Raw Materials
10.1.2 Key Raw Materials Price Trend
10.1.3 Key Suppliers of Raw Materials
10.2 Proportion of Manufacturing Cost Structure
10.3 Manufacturing Process Analysis of Oral Hypoglycemic Agents and Insulin Analogues
10.4 Oral Hypoglycemic Agents and Insulin Analogues Industrial Chain Analysis
11 Marketing Channel, Distributors and Customers
11.1 Marketing Channel
11.1.1 Direct Marketing
11.1.2 Indirect Marketing
11.2 Oral Hypoglycemic Agents and Insulin Analogues Distributors List
11.3 Oral Hypoglycemic Agents and Insulin Analogues Customers
12 Market Dynamics
12.1 Market Trends
12.2 Opportunities
12.3 Market Drivers
12.4 Challenges
12.5 Influence Factors
13 Oral Hypoglycemic Agents and Insulin Analogues Market Forecast
13.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Price Forecast
13.1.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Forecast (2021-2026)
13.1.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Forecast (2021-2026)
13.1.3 Global Oral Hypoglycemic Agents and Insulin Analogues Price Trend Forecast (2021-2026)
13.2 Global Oral Hypoglycemic Agents and Insulin Analogues Forecast by Region
13.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Forecast by Region (2021-2026)
13.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Forecast by Region (2021-2026)
13.2.3 North America Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue Growth Forecast (2021-2026)
13.2.4 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue Growth Forecast (2021-2026)
13.2.5 China Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue Growth Forecast (2021-2026)
13.2.6 Japan Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue Growth Forecast (2021-2026)
13.2.7 Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue Growth Forecast (2021-2026)
13.2.8 India Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue Growth Forecast (2021-2026)
13.3 Global Oral Hypoglycemic Agents and Insulin Analogues Forecast by Type
13.3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Forecast by Type (2021-2026)
13.3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Forecast by Type (2021-2026)
13.3.3 Global Oral Hypoglycemic Agents and Insulin Analogues Price Forecast by Type (2021-2026)
13.4 Global Oral Hypoglycemic Agents and Insulin Analogues Forecast by Application
14 Research Findings and Conclusion
15 Methodology and Data Source
15.1 Methodology/Research Approach
15.1.1 Research Programs/Design
15.1.2 Market Size Estimation
15.1.3 Market Breakdown and Data Triangulation
15.2 Data Source
15.2.1 Secondary Sources
15.2.2 Primary Sources
15.3 Author List
15.4 Disclaimer
Table 1. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) Growth Rate by Type (2015-2026)
Table 2. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) Comparison by Application (2015-2026)
Table 3. Global Market Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) Comparison by Region 2015-2026
Table 4. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) of Key Companies (2015-2020)
Table 5. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Share by Company (2015-2020)
Table 6. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) by Company (2015-2020)
Table 7. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Company (2015-2020)
Table 8. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) Market Share by Region (2015-2020)
Table 9. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Share by Region (2015-2020)
Table 10. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) Market Share by Region (2015-2020)
Table 11. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Region (2015-2020)
Table 12. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Type (2015-2020)
Table 13. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Share by Type (2015-2020)
Table 14. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) Market Share by Type (2015-2020)
Table 15. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Type (2015-2020)
Table 16. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2015-2020)
Table 17. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Share by Application (2015-2020)
Table 18. North America Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Company (2015-2020)
Table 19. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company (2015-2020)
Table 20. North America Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Type (2015-2020)
Table 21. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2015-2020)
Table 22. North America Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Application (2015-2020)
Table 23. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2015-2020)
Table 24. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Company (2015-2020)
Table 25. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company (2015-2020)
Table 26. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Type (2015-2020)
Table 27. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2015-2020)
Table 28. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Application (2015-2020)
Table 29. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2015-2020)
Table 30. China Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Company (2015-2020)
Table 31. China Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company (2015-2020)
Table 32. China Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Type (2015-2020)
Table 33. China Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2015-2020)
Table 34. China Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Application (2015-2020)
Table 35. China Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2015-2020)
Table 36. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Company (2015-2020)
Table 37. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company (2015-2020)
Table 38. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Type (2015-2020)
Table 39. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2015-2020)
Table 40. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Application (2015-2020)
Table 41. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2015-2020)
Table 42. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Company (2015-2020)
Table 43. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company (2015-2020)
Table 44. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Type (2015-2020)
Table 45. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2015-2020)
Table 46. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Type (2015-2020)
Table 47. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2015-2020)
Table 48. India Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Company (2015-2020)
Table 49. India Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company (2015-2020)
Table 50. India Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Type (2015-2020)
Table 51. India Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2015-2020)
Table 52. India Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) by Application (2015-2020)
Table 53. India Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2015-2020)
Table 54. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
Table 55. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
Table 56. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 57. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
Table 58. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
Table 59. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 60. Biocon Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
Table 61. Biocon Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
Table 62. Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 63. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
Table 64. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
Table 65. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 66. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
Table 67. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
Table 68. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 69. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
Table 70. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
Table 71. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 72. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
Table 73. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
Table 74. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 75. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Production Sites and Area Served
Table 76. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 77. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Specification and Application
Table 78. Production Base and Market Concentration Rate of Raw Material
Table 79. Key Suppliers of Raw Materials
Table 80. Oral Hypoglycemic Agents and Insulin Analogues Distributors List
Table 81. Oral Hypoglycemic Agents and Insulin Analogues Customers List
Table 82. Market Key Trends
Table 83. Key Opportunities
Table 84. Market Key Drivers
Table 85. Key Challenges
Table 86. Key Influence Factors
Table 87. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) Forecast by Regions (2021-2026)
Table 88. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) Forecast by Regions (2021-2026)
Table 89. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) Forecast by Type (2021-2026)
Table 90. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) Forecast by Type (2021-2026)
Table 91. Global Oral Hypoglycemic Agents and Insulin Analogues Price (USD/MT) Forecast by Type (2021-2026)
Table 92. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) Forecast by Application (2021-2026)
Table 93.Research Programs/Design for This Report
Table 94.Key Data Information from Secondary Sources
Table 95.Key Data Information from Primary Sources
List of Figures
Figure 1. Oral Hypoglycemic Agents and Insulin Analogues Product Picture
Figure 2. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type in 2019
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Sales Market Share of Oral Hypoglycemic Agents and Insulin Analogues by Application in 2019
Figure 6. Hospitals Examples
Figure 7. Drug Store Examples
Figure 8. Others Examples
Figure 9. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate (2015-2026)
Figure 10. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate (2015-2026)
Figure 11. China Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate (2015-2026)
Figure 12. Japan Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate (2015-2026)
Figure 13. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate (2015-2026)
Figure 14. India Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate (2015-2026)
Figure 15. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) Growth Rate (2015-2026)
Figure 16. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Company in 2019
Figure 18. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Share by Company in 2019
Figure 19. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) by Company in 2019
Figure 20. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Company in 2019
Figure 21. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Share by Region in 2019
Figure 22. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region in 2019
Figure 23. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate by Type in 2019
Figure 24. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate by Type in 2019
Figure 25. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application in 2019
Figure 26. North America Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate (2015-2020)
Figure 27. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate (2015-2020)
Figure 28. North America Oral Hypoglycemic Agents and Insulin Analogues Price (USD/MT) Trend (2015-2020)
Figure 29. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company in 2019
Figure 30. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type in 2019
Figure 31. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application in 2019
Figure 32. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate (2015-2020)
Figure 33. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate (2015-2020)
Figure 34. Europe Oral Hypoglycemic Agents and Insulin Analogues Price (USD/MT) Trend (2015-2020)
Figure 35. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company in 2019
Figure 36. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type in 2019
Figure 37. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type in 2019
Figure 38. China Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate (2015-2020)
Figure 39. China Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate (2015-2020)
Figure 40. China Oral Hypoglycemic Agents and Insulin Analogues Price (USD/MT) Trend (2015-2020)
Figure 41. China Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company in 2019
Figure 42. China Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type in 2019
Figure 43. China Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application in 2019
Figure 44. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate (2015-2020)
Figure 45. Japan Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate (2015-2020)
Figure 46. Japan Oral Hypoglycemic Agents and Insulin Analogues Price (USD/MT) Trend (2015-2020)
Figure 47. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company in 2019
Figure 48. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type in 2019
Figure 49. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application in 2019
Figure 50. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate (2015-2020)
Figure 51. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate (2015-2020)
Figure 52. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Price (USD/MT) Trend (2015-2020)
Figure 53. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company in 2019
Figure 54. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type in 2019
Figure 55. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application in 2019
Figure 56. India Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate (2015-2020)
Figure 57. India Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate (2015-2020)
Figure 58. India Oral Hypoglycemic Agents and Insulin Analogues Price (USD/MT) Trend (2015-2020)
Figure 59. India Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Company in 2019
Figure 60. India Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type in 2019
Figure 61. India Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application in 2019
Figure 62. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
Figure 63. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Revenue Share in International Market (2015-2020)
Figure 64. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Main Business and Markets Served
Figure 65. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
Figure 66. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Revenue Share in International Market (2015-2020)
Figure 67. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Main Business and Markets Served
Figure 68. Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
Figure 69. Biocon Oral Hypoglycemic Agents and Insulin Analogues Revenue Share in International Market (2015-2020)
Figure 70. Biocon Oral Hypoglycemic Agents and Insulin Analogues Main Business and Markets Served
Figure 71. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
Figure 72. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Revenue Share in International Market (2015-2020)
Figure 73. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Main Business and Markets Served
Figure 74. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
Figure 75. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Revenue Share in International Market (2015-2020)
Figure 76. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Main Business and Markets Served
Figure 77. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
Figure 78. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Revenue Share in International Market (2015-2020)
Figure 79. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Main Business and Markets Served
Figure 80. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
Figure 81. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Revenue Share in International Market (2015-2020)
Figure 82. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Main Business and Markets Served
Figure 83. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
Figure 84. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Revenue Share in International Market (2015-2020)
Figure 85. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Main Business and Markets Served
Figure 86. by Type Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate (2015-2020)
Figure 87. by Type Oral Hypoglycemic Agents and Insulin Analogues Revenue Share in International Market (2015-2020)
Figure 88. by Type Oral Hypoglycemic Agents and Insulin Analogues Main Business and Markets Served
Figure 89. Key Raw Materials Price Trend
Figure 90. Manufacturing Cost Structure of Oral Hypoglycemic Agents and Insulin Analogues
Figure 91. Manufacturing Process Analysis of Oral Hypoglycemic Agents and Insulin Analogues
Figure 92. Oral Hypoglycemic Agents and Insulin Analogues Industrial Chain Analysis
Figure 93. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate Forecast (2021-2026)
Figure 94. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate Forecast (2021-2026)
Figure 95. Global Oral Hypoglycemic Agents and Insulin Analogues Price (USD/MT) and Trend Forecast (2021-2026)
Figure 96. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share Forecast by Regions (2021-2026)
Figure 97. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share Forecast by Regions in 2025
Figure 98. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share Forecast by Regions (2021-2026)
Figure 99. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share Forecast by Regions in 2025
Figure 100. North America Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate Forecast (2021-2026)
Figure 101. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate Forecast (2021-2026)
Figure 102. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate Forecast (2021-2026)
Figure 103. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue and Growth Rate Forecast (2021-2026)
Figure 104. China Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate Forecast (2021-2026)
Figure 105. China Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate Forecast (2021-2026)
Figure 106. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate Forecast (2021-2026)
Figure 107. Japan Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate Forecast (2021-2026)
Figure 108. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate Forecast (2021-2026)
Figure 109. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate Forecast (2021-2026)
Figure 110. India Oral Hypoglycemic Agents and Insulin Analogues Sales (K MT) and Growth Rate Forecast (2021-2026)
Figure 111. India Oral Hypoglycemic Agents and Insulin Analogues Revenue (Million USD) and Growth Rate Forecast (2021-2026)
Figure 112. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share Forecast by Type (2021-2026)
Figure 113. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share Forecast by Type (2021-2026)
Figure 114. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share Forecast by Application (2021-2026)
Figure 115.Bottom-up and Top-down Approaches for This Report
Figure 116.Data Triangulation
経口血糖降下薬（OHAs）の世界市場レポート2020 Oral hypoglycemic agents (OHAs) are a group of drugs used to help reduce the amount of sugar present in the blood. They are not insulin, but they stimulate the pancreas to produce insulin. At present, China is a country with the most populous victims of diabetes, SO, China will witness a huge potent…- 経口血糖降下薬（OHA）の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Oral Hypoglyceimic Agents (OHAs) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Oral Hypogly…
- インスリンリスプロの世界市場レポート2020 Insulin lispro is synthetic insulin with a very rapid onset and short duration of action. Diabetic patients typically use it immediately before meals to prevent postprandial hyperglycemia. Its absorption is more rapid than regular insulin. It is made by reversing the amino acids lysine and proline i…
- インスリン様成長因子の世界市場レポート2020 Market Analysis and Insights: Global Insulin Like Growth Factor Market The global Insulin Like Growth Factor market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global Insulin Like Growth Factor Scope and Market Siz…
- インスリングラルギンの世界市場レポート2020 A recently published report by QY Research titled Global Insulin Glargine Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate d…